Chinese Pharmaceutical Industry Competes for Vaccine Market Share
China’s National Medical Products Administration has announced that two Chinese pharmaceutical companies, Walvax Biotechnology and Innovax, have been approved to start selling their own version of drugs previously available only through global pharmaceutical giants Pfizer, Merck and GlaxoSmithKline.1 Cecolin, developed by Innovax, will compete in the Human Papilloma Virus (HPV) arena against Merck’s Gardasil and […]
Tamiflu on Track to Be an Over-The-Counter Drug
In July 2019, drug and French vaccine manufacturer Sanofi signed a deal with Roche Pharmaceuticals to obtain exclusive over-the-counter (OTC) rights for Tamiflu (oseltamivir), an antiviral drug licensed for the treatment of influenza infections. Genentech, a member of the Roche Group, currently sells Tamiflu in the United States only for prescription use.1 Tamiflu is a […]
Vaccine Market Valued at $93 Billion by 2026
A recent report by Fortune Business Insights projects the value of the world market for vaccines to reach $93.08 billion by 2026, with a Compound Annual Growth Rate (CAGR) of 10.7 percent during the forecast period.1 One of the main drivers of the vaccine market is the need for greater supplies of vaccines, given stricter government […]
GlaxoSmithKline Partners with Viome to Develop New Vaccines
Vaccine manufacturer GlaxoSmithKline (GSK) of the United Kingdom has partnered with Viome, a gut microbiome test company in Seattle, Washington to better understand bacteria that live in the digestive tract and the role they play in the body’s immune system response.1 According to Emmanuel Hanon, senior vice president for research and development at GSK Vaccines, […]
Novartis Manipulated Data in FDA Biologics License Application
On Aug. 6, 2019, the U.S. Food and Drug Administration (FDA) issued a statement saying that Swiss pharmaceutical company Novartis AG submitted a biologics license application (BLA) for the spinal muscular atrophy (SMA) gene therapy Zolgensma (onasemnogene abeparvovec-xioi) with manipulated data and failed to inform regulators until June 28, 2019—more than a month after the […]
Pfizer Fined Again for Violating Drug Laws
Colombia’s national regulatory agency, the Superintendency of Industry and Commerce (SIC), has fined pharmaceutical company Pfizer $25,000 for allegedly inflating the price of several prescription drugs it sold in that country.1 2 On July 31, 2019, the agency stated: The decision was taken after verifying information related to PFIZER SAS’ commercial operations between July and December […]
